← All trials
NCT06502990
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2024
- Primary completion
- Sep 30, 2026
- Completion date
- Sep 30, 2026
- First posted
- Jul 16, 2024
- Last posted
- Jul 16, 2024
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Amryt Research LimitedLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.